Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide injection and other GLP-1 receptor agonists have become widely used for weight loss, but pregnancy changes the clinical picture entirely. Current evidence does not support using semaglutide during pregnancy, and healthcare providers recommend discontinuing the medication before conception or immediately after a positive pregnancy test. Understanding the safety data and your options is critical if you're considering pregnancy while on weight loss therapy.
Why Semaglutide Is Not Recommended During Pregnancy
Semaglutide has never been studied in pregnant human subjects, which means there is no clinical safety data from controlled trials. All available evidence comes from animal reproduction studies, which showed effects on fetal development and organ formation at doses comparable to human therapeutic levels. The FDA pregnancy category for semaglutide reflects this uncertainty: the medication is classified such that use in pregnancy is generally not recommended unless the benefit clearly outweighs the potential risk.
The biological mechanism of GLP-1 receptor agonists—increasing insulin secretion and altering glucose metabolism—could theoretically affect placental function and fetal growth, though the exact risks in human pregnancy remain unknown. Animal studies have documented increased rates of skeletal abnormalities and delayed fetal development, findings that have prompted major medical organizations to issue cautionary guidance. Because pregnancy involves rapid physiological changes and the developing fetus is uniquely vulnerable, the conservative approach endorsed by obstetrics and endocrinology societies is to avoid semaglutide throughout all nine months.
Current Clinical Evidence and Professional Recommendations
The American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society, and the American Diabetes Association all recommend stopping GLP-1 medications before attempting to become pregnant. These organizations note that weight management remains important during and after pregnancy, but the risk-benefit calculation changes fundamentally once conception occurs. No prospective trials are planned to test semaglutide safety in pregnancy, meaning physicians must rely on animal data and the precautionary principle.
Emerging real-world data from pregnancy registries and case reports are beginning to accumulate as more patients have become pregnant while using GLP-1 medications, but these observational reports do not yet constitute evidence of safety. Healthcare providers are tracking outcomes in a post-marketing surveillance framework, yet the lack of intentional clinical studies means definitive answers about long-term fetal effects may take years to establish. In the interim, the standard recommendation is complete discontinuation at least one menstrual cycle before attempting conception, or immediately upon discovery of pregnancy.
Planning Pregnancy: Timing and Alternatives
If you are taking semaglutide injection and planning to become pregnant, your first step is to schedule a conversation with both your weight loss provider and your obstetrician or primary care doctor. These discussions should address your weight loss goals, your timeline for conception, and realistic expectations for weight management during pregnancy. Stopping semaglutide 4–6 weeks before attempting conception allows the medication to clear your system and gives your metabolism time to stabilize.
During pregnancy and the postpartum period, weight management shifts toward gentler, evidence-based strategies: structured nutrition counseling, appropriate physical activity as cleared by your OB-GYN, and behavioral support. Some patients regain weight after stopping semaglutide, while others maintain losses through lifestyle alone. After weaning from breastfeeding (if applicable), you and your provider can reassess whether resuming GLP-1 therapy aligns with your health goals and family planning.
Accessing Personalized Guidance Through PlexusDx
PlexusDx compounded semaglutide injection (starting at $149/mo) is prescribed only after consultation with a healthcare provider who reviews your medical and reproductive history. If you are pregnant, planning pregnancy, or have questions about medication safety during conception and childbearing, your PlexusDx medical team will guide you toward safe, appropriate alternatives and timing strategies. The company serves all 50 states without requiring insurance, and HSA/FSA accounts can be used to cover treatment costs, making expert guidance accessible regardless of insurance status.
For patients seeking to understand their individual response to weight loss medications and genetic predispositions to obesity, PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month). This test maps 14 peptide pathways and 150+ genetic insights, helping your provider make informed decisions about treatment resumption after pregnancy. Understanding your genetic profile can inform conversations about which medication and timeline best suit your post-pregnancy health plan.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What should I do if I become pregnant while taking semaglutide?
Stop the medication immediately and contact your OB-GYN and prescribing provider on the same day. Discontinuing a single or a few doses is not associated with fetal harm, and early intervention is the safest approach. Your care team will establish a prenatal monitoring plan and discuss weight management strategies appropriate for each trimester.
Is there any clinical evidence that semaglutide is safe in pregnancy?
No human clinical trials have tested semaglutide in pregnant subjects, so definitive safety evidence does not exist. Animal studies showed concerns about fetal development, and medical organizations universally recommend avoiding GLP-1 medications during pregnancy. Real-world pregnancy registries are being monitored, but current guidance is based on precaution rather than proven safety.
How long after stopping semaglutide can I try to conceive?
Most providers recommend waiting one full menstrual cycle (4–6 weeks) after your last semaglutide injection before attempting pregnancy. This allows the medication to clear and your glucose metabolism to normalize. Your doctor may adjust this timeline based on your individual medical history and fertility status.
Will I regain weight after stopping semaglutide to get pregnant?
Weight regain is common but not universal after stopping GLP-1 medications. Intensive behavioral support, structured nutrition, and appropriate exercise during and after pregnancy can help minimize regain. Some patients maintain significant weight losses through lifestyle change alone, while others may resume treatment postpartum after discussion with their providers.
Can PlexusDx help me plan medication timing around pregnancy?
Yes. PlexusDx prescribers review your reproductive goals and medical history before dispensing semaglutide injection or any GLP-1 therapy. If you are planning pregnancy, your provider will help you establish a safe discontinuation timeline and discuss resumption strategies post-pregnancy. The PlexusDx Precision Peptide Genetic Test can also inform personalized approaches to treatment after childbearing.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Will Insurance Cover Ozempic for Weight Loss? Understanding Your Coverage Options
Understanding Who Cannot Take Wegovy: A Guide to Safe and Personalized Weight Loss